Audentes Therapeutics (BOLD)

42.81 +1.96 (4.80%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/9/18 *Est.)

Latest Headlines

Evercore ISI Weighs in on Sector Implications Following Sarepta 'Dramatic' Gene Therapy Results June 19, 2018 1:17 PM - StreetInsider Form 4 Audentes Therapeutics, For: Jun 08 Filed by: Smith Julie June 8, 2018 5:25 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 08 Filed by: Schuetz Thomas J. June 8, 2018 5:24 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 08 Filed by: PARMAR KUSH June 8, 2018 5:24 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 08 Filed by: Morrison Scott W June 8, 2018 5:23 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 08 Filed by: LANGE LOUIS G June 8, 2018 5:22 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 08 Filed by: Jarrett Jennifer June 8, 2018 5:22 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 08 Filed by: Goldberg Mark Alan June 8, 2018 5:21 PM - SEC Filing Form 8-K Audentes Therapeutics, For: Jun 08 June 8, 2018 5:16 PM - SEC Filing Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy June 5, 2018 8:00 AM - PR NewsWire Form 4 Audentes Therapeutics, For: Jun 01 Filed by: Holles Natalie C. June 4, 2018 4:49 PM - SEC Filing Audentes Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference May 29, 2018 8:00 AM - PR NewsWire Form 4 Audentes Therapeutics, For: May 21 Filed by: Patterson Matthew R May 23, 2018 6:14 PM - SEC Filing UPDATE: Audentes Therapeutics (BOLD) PT Raised to $38 at Mizuho Securities; 'New AT-132 Data Looks Promising' May 21, 2018 4:03 AM - StreetInsider Audentes Therapeutics (BOLD) PT Raised to $40 at H.C. Wainwright May 17, 2018 7:10 AM - StreetInsider Audentes Therapeutics (BOLD) Plunges 7.5% After Reporting Data from Phase 1/2 Clinical Trial of AT132 in patients with XLMTM May 16, 2018 11:36 AM - StreetInsider Form 8-K Audentes Therapeutics, For: May 16 May 16, 2018 11:32 AM - SEC Filing Audentes Therapeutics (BOLD) Announces Continuing Positive Data from First Dose Cohort of ASPIRO May 16, 2018 11:30 AM - StreetInsider Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy May 16, 2018 11:30 AM - PR NewsWire Form 10-Q Audentes Therapeutics, For: Mar 31 May 10, 2018 4:48 PM - SEC Filing Pre-Open Movers 05/10: (ARMO) (HEAR) (VTVT) Higher; (MDCA) (NUAN) (BKNG) Lower (more...) May 10, 2018 9:14 AM - StreetInsider Audentes Therapeutics (BOLD) PT Lowered to $43 at Leerink Partners May 10, 2018 7:21 AM - StreetInsider Audentes Therapeutics (BOLD) PT Raised to $30 at Evercore ISI May 10, 2018 1:10 AM - StreetInsider Audentes Therapeutics (BOLD) PT Lowered to $41 at BMO Capital May 10, 2018 1:09 AM - StreetInsider After-Hours Stock Movers 05/09: (HEAR) (VTVT) (RESN) Higher; (NUAN) (SYNA) (BKNG) Lower (more...) May 9, 2018 6:30 PM - StreetInsider Audentes Therapeutics (BOLD) Tops Q1 EPS by 6c May 9, 2018 4:24 PM - StreetInsider Form 8-K Audentes Therapeutics, For: May 09 May 9, 2018 4:23 PM - SEC Filing Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update May 9, 2018 4:01 PM - PR NewsWire Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018 May 9, 2018 8:00 AM - PR NewsWire Audentes Therapeutics (BOLD) Names Natalie Holles President and COO May 8, 2018 8:10 AM - StreetInsider Form 4 Audentes Therapeutics, For: May 07 Filed by: Holles Natalie C. May 8, 2018 8:09 AM - SEC Filing Form 8-K Audentes Therapeutics, For: May 08 May 8, 2018 8:06 AM - SEC Filing Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer May 8, 2018 8:00 AM - PR NewsWire Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018 May 2, 2018 8:00 AM - PR NewsWire Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy April 30, 2018 1:14 PM - PR NewsWire Form DEFA14A Audentes Therapeutics, April 27, 2018 5:57 PM - SEC Filing Form DEF 14A Audentes Therapeutics, For: Jun 08 April 27, 2018 5:56 PM - SEC Filing Form CT ORDER Audentes Therapeutics, April 23, 2018 1:40 PM - SEC Filing Form 4 Audentes Therapeutics, For: Apr 02 Filed by: Patterson Matthew R April 4, 2018 9:03 PM - SEC Filing Form 4 Audentes Therapeutics, For: Mar 15 Filed by: NEWMAN MARY April 2, 2018 9:07 PM - SEC Filing Form 4 Audentes Therapeutics, For: Mar 29 Filed by: PRASAD SUYASH March 29, 2018 8:24 PM - SEC Filing Form S-3ASR Audentes Therapeutics, March 29, 2018 4:53 PM - SEC Filing Form 4 Audentes Therapeutics, For: Mar 26 Filed by: PRASAD SUYASH March 28, 2018 9:13 PM - SEC Filing Form 4 Audentes Therapeutics, For: Mar 26 Filed by: LANGE LOUIS G March 28, 2018 9:12 PM - SEC Filing Full Article List